Evidence map›Paper›PMID 42028206›Full record

ArticleRSC advances2026

Discovery of thieno[2,3-

Hamed W El-Shafey, Abdelrahman Hamdi, Mohamed R Elnagar, Sahar M Gebril, Abdullah Haikal, Adel S El-Azab, Simone Brogi, Ibrahim A Al-Suwaidan, Alaa A-M Abdel-Aziz

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Selected Thieno[2,3-Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hamed W El-ShafeyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt abdelrahmanhamdi2012@mans.edu.eg.ORCID https://orcid.org/0000-0002-7848-8785
Abdelrahman HamdiDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt abdelrahmanhamdi2012@mans.edu.eg.ORCID https://orcid.org/0000-0002-0196-1976
Mohamed R ElnagarDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University Cairo 11823 Egypt.ORCID https://orcid.org/0000-0003-0434-2369
Sahar M GebrilDepartment of Histology and Cell Biology, Faculty of Medicine, Sohag University Sohag 82524 Egypt.ORCID https://orcid.org/0000-0002-8679-4897
Abdullah HaikalDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University Mansoura 35516 Egypt.ORCID https://orcid.org/0000-0003-2548-3507
Adel S El-AzabDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University P. O. Box 2457 Riyadh 11451 Saudi Arabia.ORCID https://orcid.org/0000-0001-7197-1515
Simone BrogiDepartment of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy.ORCID https://orcid.org/0000-0001-9375-6242
Ibrahim A Al-SuwaidanDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University P. O. Box 2457 Riyadh 11451 Saudi Arabia.ORCID https://orcid.org/0000-0002-7547-4193
Alaa A-M Abdel-AzizDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University P. O. Box 2457 Riyadh 11451 Saudi Arabia.ORCID https://orcid.org/0000-0002-3362-9337

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer continues to be the most common malignancy in women and a major contributor of cancer-related mortality, emphasizing the need for novel therapeutic agents. A novel series of thienopyrimidine analogues were designed as dual Aurora B and VEGFR-2 inhibitors. Among them, compound M1 showed the highest potency, displaying strong cytotoxicity against breast MCF-7 (IC

Identifiers

PMID42028206
PMCPMC13100712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.